Sclerostin单克隆抗体:即将出现的治疗骨质疏松症的新药物

Sclerostin monoclonal antibody:A future new drug for the treatment of osteoporosis

骨质疏松是一种很常见的骨病,主要表现为单位体积内骨量减少、骨密度及骨强度的下降,加大骨折的风险增加。目前骨质疏松的药物治疗方法主要有:(1)激素替代治疗,(2)钙剂及维生素D,(3)抑制骨吸收,(4)促进骨形成,(5)中药治疗。Sclerostin是由骨细胞分泌的一种糖蛋白,拮抗性结合到LRP6和LRP6,阻断成骨细胞中Wnt信号/β-catenin信号,从而抑制成骨细胞分化、活动和生存。其作用机制使得Sclerostin成为治疗骨质疏松的一个新的靶点。目前,作用于Sclerostin的Sclerostin单克隆抗体已经进行了动物实验及临床前实验。实验结果显示Sclerostin单克隆抗体能促进骨形成,增加骨密度。目前Sclerostin单克隆抗体的安全性仍需进一步研究,但对治疗人类骨质疏松症有广阔的前景。

Osteoporosis is a common bone disease with main manifestations of bone mass decreasing, bone mineral density and bone strength decreasing, and fracture risk increasing. The drug therapies for the treatment of osteoporosis are mainly hormone substitute therapy, calcium and vitamin, inhibiting bone absorption, promoting bone formation, and traditional Chinese medicine. Sclerostin is a glycoprotein secreted by osteocyte and can bind to LRP6 to block the Writ signal and β-catenin signal and to inhabit the differentiation, action, and survival of osteoblast. Sclerostin has become a new drug target for the treatment of osteoporosis because of its mechanism. Recently, sclerostin monoclonal antibody has been conducted to the animal experimental and pre-elinical experiment. The results of experiments show that sclerostin monoclonal antibody can promote bone formation to increase bone density. The safety of sclerostin needs to be further researched, however, it bring a new view for the treatment of osteoporosis.